Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics has announced the dosing of the first patient in a Phase 1 trial for Briquilimab, an antibody therapy targeting c-Kit (CD117) for lower-risk myelodysplastic syndromes (LR-MDS). The single-arm Phase 1 trial will evaluate briquilimab's safety and tolerability as a second-line therapy in subjects with LR-MDS. The trial will employ a dose escalation design to identify the optimal..